Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis

M. Furue; K. Yamamura; M. Kido-Nakahara; T. Nakahara; Y. Fukui

doi:10.1111/all.13239

Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis

M. Furue, K. Yamamura, M. Kido-Nakahara, T. Nakahara, Y. Fukui

研究成果: ジャーナルへの寄稿 › 総説 › 査読

185 被引用数 (Scopus)

抄録

Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (T_H2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from T_H2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

本文言語	英語
ページ（範囲）	29-36
ページ数	8
ジャーナル	Allergy: European Journal of Allergy and Clinical Immunology
巻	73
号	1
DOI	https://doi.org/10.1111/all.13239
出版ステータス	出版済み - 1月 2018

!!!All Science Journal Classification (ASJC) codes

免疫アレルギー学
免疫学

文献へのアクセス

10.1111/all.13239

他のファイルとリンク

引用スタイル

@article{0bafa651589e4928a8a13cb765a1ce1f,

title = "Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis",

abstract = "Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.",

keywords = "T helper 2, atopic dermatitis, interleukin-31, interleukin-31 receptor, pruritus",

author = "M. Furue and K. Yamamura and M. Kido-Nakahara and T. Nakahara and Y. Fukui",

note = "Publisher Copyright: {\textcopyright} 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2018",

month = jan,

doi = "10.1111/all.13239",

language = "English",

volume = "73",

pages = "29--36",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis

AU - Furue, M.

AU - Yamamura, K.

AU - Kido-Nakahara, M.

AU - Nakahara, T.

AU - Fukui, Y.

PY - 2018/1

Y1 - 2018/1

N2 - Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

AB - Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

KW - T helper 2

KW - atopic dermatitis

KW - interleukin-31

KW - interleukin-31 receptor

KW - pruritus

UR - http://www.scopus.com/inward/record.url?scp=85025435358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025435358&partnerID=8YFLogxK

U2 - 10.1111/all.13239

DO - 10.1111/all.13239

M3 - Review article

C2 - 28670717

AN - SCOPUS:85025435358

SN - 0105-4538

VL - 73

SP - 29

EP - 36

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 1

ER -

Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis

抄録

!!!All Science Journal Classification (ASJC) codes

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル